Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The First Line of Therapy in Severe Migraine Attacks More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Our client is looking for partners to further develop and commercialize stem cells, sourced from adipose tissue for the treatment of regenerative medicine and ageing. More
A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune. More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
A novel non-invasive method for using carbon-13 magnetization transfer effects to determine and evaluate in vivo aspartate transaminase (AST) activity and levels in an organ, as a biomarker of disease and certain neurological disorders. More
Posidorm is an unique surge sustained formulation of melatonin that provides 0.5mg of melatonin as an immediate release to promote sleep and 1.0mg as sustained release over several hours to maintain sleep More
These radioactive compounds have the very unique and unprecedented ability to bind very specifically and irreversibly to butyrylcholinesterase (BChE). More
Treatment of movement disorders associated with organic central nervous system conditions, e.g. Huntington's chorea, hemiballismus and senile chorea. More
Biomarker and possible therapeutic target for a variety of neurodegenerative diseases More
Related Reports
Market Research Reports provided by reports.iptechex.com
Feb 2011 - 75 pages - $1,000
Jun 2006 - 1068 pages - $2,495
Sep 2011 - 97 pages - $3,500
Oct 2010 - 53 pages - $1,000
Nov 2010 - 40 pages - $500
Jun 2011 - 25 pages - $1,000
Nov 2010 - 50 pages - $500
May 2011 - 118 pages - $3,500
Jan 2010 - $75
Jun 2011 - 24 pages - $1,000
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Attention-deficit/hyperactivity disorder
- Autism
- Brain injury
- Cerebral palsy
- Cerebrovascular disorders
- Dyslexia
- Emesis
- Encephalitis
- Epilepsy
- Huntington's disease
- Hypersomnia
- Insomnia
- Meningitis, aseptic
- Meningitis, bacterial
- Meningitis, viral
- Migraine
- Myalgic encephalomyelitis
- Narcolepsy
- Neoplastic meningitis
- Nerve regeneration
- Neuropathy, AIDS-related
- Neuropathy, diabetic
- Neuropathy, peripheral
- Neuroprotection
- Premenstrual dysphoric disorder
- Sleep apnea
- Sleep disorders
- Spasticity
- Spinal cord injury
- Stroke
- Tourette's syndrome
- Vertigo
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us